American Century Companies Inc. Buys 665,208 Shares of Enovis Co. (NYSE:ENOV)

American Century Companies Inc. boosted its stake in Enovis Co. (NYSE:ENOV) by 78.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,511,871 shares of the company’s stock after purchasing an additional 665,208 shares during the quarter. American Century Companies Inc. owned approximately 2.76% of Enovis worth $68,337,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. DAVENPORT & Co LLC boosted its position in shares of Enovis by 5.5% during the 1st quarter. DAVENPORT & Co LLC now owns 1,982,452 shares of the company’s stock valued at $123,804,000 after acquiring an additional 103,027 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Enovis by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 849,023 shares of the company’s stock valued at $53,022,000 after buying an additional 20,720 shares in the last quarter. Magnetar Financial LLC raised its holdings in shares of Enovis by 10.9% during the 1st quarter. Magnetar Financial LLC now owns 662,752 shares of the company’s stock valued at $41,389,000 after buying an additional 65,319 shares in the last quarter. Artemis Investment Management LLP raised its holdings in shares of Enovis by 17.6% during the 1st quarter. Artemis Investment Management LLP now owns 588,491 shares of the company’s stock valued at $36,737,000 after buying an additional 87,999 shares in the last quarter. Finally, Boone Capital Management LLC raised its holdings in shares of Enovis by 11.9% during the 4th quarter. Boone Capital Management LLC now owns 562,739 shares of the company’s stock valued at $31,525,000 after buying an additional 60,008 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ENOV shares. Evercore ISI decreased their price objective on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. JPMorgan Chase & Co. decreased their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Finally, Needham & Company LLC decreased their price objective on Enovis from $82.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.13.

Enovis Price Performance

Shares of ENOV stock opened at $43.34 on Monday. The firm has a market cap of $2.38 billion, a P/E ratio of -28.89 and a beta of 1.92. Enovis Co. has a fifty-two week low of $39.98 and a fifty-two week high of $65.03. The business’s 50 day moving average price is $44.86 and its 200-day moving average price is $50.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.03. The firm had revenue of $525.20 million for the quarter, compared to analyst estimates of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The business’s quarterly revenue was up 22.6% compared to the same quarter last year. During the same period last year, the company earned $0.61 EPS. On average, equities research analysts anticipate that Enovis Co. will post 2.7 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.